Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Richard Carvajal, MD
Phone
(646) 317-6041
Email
rdc2150@cumc.columbia.edu

As the Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, Dr. Carvajal is focused on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases.

To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel therapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere. Working closely with the laboratory scientists, the group is using the techniques of molecular biology to identify specific proteins, genes, or other molecules that influence the growth of each person's cancer, with the goal of selecting the most promising therapies for individual patients.

Dr. Carvajal's melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet, or under the fingernails (acral melanomas). Although these tumors arise from pigment cells of the body just as do the more common melanomas that arise from the skin (cutaneous melanomas), they are clinically and biologically distinct from cutaneous disease. Once metastatic (that is, spread from where it originally began to other sites in the body), these diseases have proven to be difficult to treat.

In an advance that helped to launch a new era of personalized medicine in melanoma therapy, Dr. Carvajal has led a clinical trial of imatinib (Gleevec) in patients with melanoma characterized by the presence of a mutation in a gene called KIT. While this mutation is rare in cutaneous melanoma, it is found in about 20% of mucosal and acral melanomas. Based in part on the positive results of this trial, where long-lasting tumor responses were observed in patients with these diseases, the use of imatinib in melanomas harboring KIT mutations was added to the National Comprehensive Cancer Network guidelines for the treatment of melanoma.

Uveal melanoma is characterized by mutations in genes called GNAQ and GNA11 that lead to activation of a growth pathway called the MAPK pathway. Before 2013, there were no effective treatments for metastatic disease; however, another trial that Dr. Carvajal has developed and conducted identified selumetinib, a medicine that blocks the MAPK pathway, as the first effective treatment for patients with advanced uveal melanoma.

Dr. Carvajal's research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation, the Empire Clinical Research Investigator Program, and the generous philanthropic support of our patients and their families. He has authored or co- authored more than 50 peer-reviewed manuscripts, books, and book chapters.

In addition to Dr. Carvajal's work at Columbia University Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research UK to enhance international collaboration in the conduct of clinical trials for uveal melanoma.


Clinical Studies Managed By Dr. Carvajal:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with uveal melanoma using study drug AEB071Novartis Pharmaceuticals CorporationAAAN4901
Details[CLOSED] A study for patients with advanced and/or refractory solid tumors using oral drug CB-839Calithera Biosciences, IncAAAO1854
Details[CLOSED] A study for patients with advanced melanoma using study drug TH-302Threshold PharmaceuticalsAAAO5759
Details[CLOSED] A study for patients with select advanced cancers using study drug INCB24360InCyteAAAO2406
Details[CLOSED] A study for patients with advanced cancers using oral study drug MGCD265Mirati Therapeutics Inc.AAAP0559
Details[CLOSED] Study for patients with melanoma, non-small cell lung cancer (NSCLC) or squamous cell cancer of the head and neck (SCCHN) using drug B7-H3MacroGenics, IncAAAP0812
Details[CLOSED] Study for patients with Uveal Melanoma using study drug crizotinibPfizerAAAO8010
Details[CLOSED] A dose escalation study of trial drug PF-06650808 in patients with advanced solid tumorsPfizerAAAP2506
Details[CLOSED] A study for patients with advanced malignancies using study drug REGN2810 in combination with other anti-cancer therapiesRegeneronAAAP2403
Details[CLOSED] A study for patients with melanoma using study drug talimogene laherparepvecAmgenAAAP3756
Details[CLOSED] A study for patients with Melanoma, Squamous Cell Cancer of the Head and Neck, or Non-Small Cell Lung cancer using study drug MGA271MacrogenicsAAAP4013
Details[CLOSED] A study for patients with advanced Uveal Melanoma using study drug IMCgp100ImmunocoreAAAQ4601
Details[CLOSED] A study for men with non-metastatic prostate cancer using study drugs enzalutamide, Enzalutamide Monotherapy, and Placebo Plus LeuprolideMedivationAAAP8857
Details[CLOSED] A study for patients with advanced solid tumors using study drug IMC-CS4Eli Lilly and CompanyAAAQ8124
Details[CLOSED] A study for patients with Acute Myeloid Leukemia (AML) using study drug decitabineJanssen Research & Development, LLCAAAQ6852
DetailsA study for patients with incurable cancers using study drug CPI-444Corvus Pharmaceuticals, Inc.AAAQ6651
Details[CLOSED] A study for patients with advanced solid tumors using study drug MEDI1873MedImmuneAAAQ7429
Details[CLOSED] A study for patients with advanced solid tumors using study drug MEDI0562MedImmuneAAAQ7663
DetailsA study for patients with advanced solid tumors using study drug NivolumabBristol-Myers SquibbAAAQ8652
Details[CLOSED] A study for patients with advanced melanoma using study drug Talimogene LaherparepvecAmgen Inc.AAAQ6504
Details[CLOSED] A study for patients with advanced solid tumors study drug durvalumab (MEDI4736)Eli Lilly and CompanyAAAQ8659
DetailsA study for patients with Uveal Melanoma using the study drug SelumetinibAstraZenecaAAAQ6999
Details[CLOSED] A study for patients with solid tumors, lymphoma, acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) using study drug PLX51107PlexxikonAAAQ9209
Details[CLOSED] Study of efficacy and safety of cobimetinib plus atezolizumab in patients with untreated melanomaGenentechAAAR4467
Details[CLOSED] A Dose Escalation Trial of AEB102 in Patients with Advanced Solid TumorsAgela Biotherapeutics, Inc.AAAR1316
DetailsSafety and Efficacy Study of IMCgp100 in Patients with Previously Untreated Advanced Uveal MelanomaImmunocoreAAAR2515
Details[CLOSED] Study of Epacadostat and Pembrolizumab in Patients Advanced Gastrointestinal Stromal Tumors (GIST)Incyte CorporationAAAR1581
Details[CLOSED] Study of LAG525 Alone and in Combination with PDR001 in Patients with Advanced MalignanciesNovartisAAAP4008
DetailsMolecular Analysis for Therapy Choice (MATCH)ECOG- ACRINAAAP9159
DetailsStudy of Drug in Patients with Advanced Solid Tumor MalignanciesMethylGene Inc.AAAO0006
Details[CLOSED] Study of LXS196 in Patients with Uveal MelanomaNovartisAAAR6254
DetailsStudy of Anti-Tumor Activity and Potential Predictors of Response in Patients with Melanoma (Advanced Mucosal or Acral Letiginous Melanoma)BMSAAAR1551
DetailsStudy of Drug in Subjects with Advanced MalignanciesPlexxikon Inc.AAAR7748
DetailsStudy of Drug in Subjects with Advanced Solid TumorsAstrellas Pharma Global DevelopmentAAAR5080
DetailsStudy of Nivolumab in Patients with Resected Stage IIB/IIC MelanomaThomas Jefferson UniversityAAAR9042
DetailsStudy of AZD1775 in Patients with CCNE1 Amplification (Skin Cancer or Melanoma)National Cancer Institute NCIAAAS1468
DetailsStudy of Dabrafenib, Trametinib, and Navitoclax in BRAF-Mutant Melanoma and Other Solid TUmorsNational Cancer Institute NCIAAAS2517
DetailsStudy of Ipilimumab in Combination with Nivolumab in Subjects with High-risk Ocular MelanomaHoosier Cancer Research Network and BMSAAAR9971
DetailsStudy of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced CancersRegeneron Pharmaceuticals, Inc.AAAS1963
DetailsStudy of Encorafenib + Binimetinib in Patients wit hBRAFV600-Mutant Melanoma Brain MetastasisArray BioPharma Inc.AAAS3457
DetailsStudy of IDE196 in Patients with Solid TumorsIDEAYA BiosciencesAAAS4168
DetailsCemiplimab Survivorship Epidemiology (CASE) StudyRegeneron PharmaceuticalsAAAS3659
DetailsStudy of LN-145 in the Treatment of Squamous Cell Carcinoma of the Head & Neck or Non Small Cell Lung Cancer (NSCLC)Iovance Biotherapeutics, Inc.AAAS5355
DetailsImmatics Biomarker ScreeningImmatics US, Inc.AAAS6510
DetailsStudy of Cemiplimab in Cutaneous Squamous Cell CarcinomaRegeneron Pharmaceuticals, Inc.AAAS4125
DetailsStudy of Avelumab + Cetuximab vs. Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the SkinNIHAAAS5053